Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 6961-6970 Newer>

The Motley Fool December 14, 2010 Brian Orelli	Another Mishap for a Drugmaker That Can't Afford It Eli Lilly puts cancer drug tasisulam on a clinical hold.
The Motley Fool December 14, 2010 Brian Orelli	3 Ways to Play Biotech With Options Are you looking for a way for options to help you decrease the risk of investing in biotechnology? Then read on.
The Motley Fool December 14, 2010 Seth Jayson	Why the Street Should Love Teva Pharmaceutical's Earnings Over the past 12 months, Teva Pharmaceutical generated $3,303.0 million in free cash flow on net income of $2,939.0 million.
The Motley Fool December 13, 2010 Sean Williams	This Is the Investing Equivalent of Dumb and Dumber The story of Tenet Healthcare and Community Health Services shows what happens when too much debt meets declining business model.
The Motley Fool December 13, 2010 Brian Orelli	Yep, We Still Want to Lowball You sanofi-aventis still wants investors shares in Genzyme, but it's not willing to step up the price.
The Motley Fool December 13, 2010 Seth Jayson	Here's How Lincare Holdings May Be Failing You Here's the current margin snapshot for home oxygen company Lincare Holdings and some of its sector and industry peers and direct competitors.
The Motley Fool December 13, 2010 Seth Jayson	Are McKesson's Earnings Better Than they Look? With questionable cash flows amounting to only 2.1% of operating cash flow, McKesson's cash flows look clean.
The Motley Fool December 10, 2010 Brian Orelli	Was This Drug Destined for Failure? Pfizer announces that it's pulling Thelin off the market, and withdrawing the marketing application with the Food and Drug Administration, because a new side effect was discovered.
The Motley Fool December 10, 2010 Sean Williams	ICU Medical: Bargain or Value Trap? International sales growth will be the key to the medical supplier's long-term success.
The Motley Fool December 10, 2010 Brian Orelli	Something Is Better Than Nothing, I Guess Novartis' Zometa fails a critical clinical trial.
<Older 6961-6970 Newer> Return to current articles.